Finance

Lists
TAK:NYSE
Takeda Pharmaceutical Co Ltd
USD 21,77
+1,59%
(+0,34) 1D
USD 22,09
+1,47% (+0,32)
After hours
Closed: 20 Nov., 16:00:04 GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for TAK...
Open
USD 21,82
High
USD 22,07
Low
USD 21,74
Mkt. cap
71,06 mjd.
Avg. vol.
3,15 m.
Volume
3,80 m.
Dividend
2,90%
Quarterly dividend
USD 0,16
Ex-dividend date
30 Mrt. 2027
P/E ratio
332,01
52-wk high
USD 22,07
52-wk low
USD 14,09
EPS
USD 0,07
Beta
-0,01
Shares outstanding
3,20 mjd.
No. of employees
47 k
Open
USD 21,82
High
USD 22,07
Low
USD 21,74
Mkt. cap
71,06 mjd.
Avg. vol.
3,15 m.
Volume
3,80 m.
Dividend
2,90%
Quarterly dividend
USD 0,16
Ex-dividend date
30 Mrt. 2027
P/E ratio
332,01
52-wk high
USD 22,07
52-wk low
USD 14,09
EPS
USD 0,07
Beta
-0,01
Shares outstanding
3,20 mjd.
No. of employees
47 k
News stories
From web sources and news partners
Profile
The Takeda Pharmaceutical Company Limited is a Japanese multinational pharmaceutical company. It is the largest pharmaceutical company in Japan, third largest such company in Asia behind Sinopharm and Shanghai Pharmaceuticals, and one of the top 20 largest pharmaceutical companies in the world by revenue. The company has over 49,578 employees worldwide and achieved US$19.299 billion in revenue during the 2018 fiscal year. The company is focused on oncology, rare diseases, neuroscience, gastroenterology, plasma-derived therapies and vaccines. Its headquarters is located in Chuo-ku, Osaka, and it has an office in Nihonbashi, Chuo, Tokyo. In January 2012, Fortune Magazine ranked the Takeda Oncology Company as one of the 100 best companies to work for in the United States. As of 2015, Christophe Weber was appointed as the CEO and president of Takeda. In 2026, Julie Kim was noted in a news item as "CEO-elect". Wikipedia
About Takeda Pharmaceutical Co Ltd
CEOChristophe Weber | Christophe Weber
Employees47 k
Founded12 Jun. 1781
Headquarters-
SectorHealth Care
IndustryPharmaceutical industry
Websitetakeda.com
Analyst ratings
Based on 1 analyst giving stock ratings to TAK in the past 3 months
Buy
Buy
1
Hold
0
Sell
0
12-month forecast
Based on 1 Wall Street analyst offering 12-month price targets for TAK in the last 3 months
Highest
Current USD 21,77
USD 50,46 (+131,77%)
Average
USD 50,46 (+131,79%)
Lowest
USD 50,46 (+131,77%)
Analyst
Recommendation
Action
Price target
Projected
Date
Koichi Mamegano
Bank of America Securities
Buy
Reiterated
JP¥8 000,00
+36 647,8%
11/16/2026
Michael Nedelcovych
TD Cowen
Buy
Maintained
USD 21,00
-3,5%
06/04/2026
Last report
29 Okt. 2026
Fiscal period
Q2 2026
JP¥77,50 / -
0,00%miss
Revenue / Est. (JPY)
1,19 bn. / 1,16 bn.
+2,71%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in JPY
Loading Previous Earnings...
Revenue
Net income
All values in JPY
Des. 2025
Mrt. 2026
Jun. 2026
Sep. 2026
Revenue
1,19 bn.
1,09 bn.
1,22 bn.
1,19 bn.
Cost of goods sold
401,15 mjd.
453,33 mjd.
406,68 mjd.
392,09 mjd.
Cost of revenue
401,15 mjd.
453,33 mjd.
406,68 mjd.
392,09 mjd.
Research and development expenses
175,23 mjd.
187,96 mjd.
167,40 mjd.
171,23 mjd.
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
282,78 mjd.
291,96 mjd.
286,51 mjd.
271,71 mjd.
Operating expense
661,30 mjd.
519,65 mjd.
612,60 mjd.
503,56 mjd.
Total operating expenses
1,06 bn.
972,98 mjd.
1,02 bn.
895,65 mjd.
Operating income
129,25 mjd.
121,56 mjd.
200,62 mjd.
291,45 mjd.
Other non operating income
-197,22 mjd.
181,53 mjd.
-3,54 mjd.
-50,69 mjd.
EBT including unusual items
133,86 mjd.
-455,02 mjd.
162,72 mjd.
155,97 mjd.
EBT excluding unusual items
114,17 mjd.
71,49 mjd.
161,92 mjd.
242,09 mjd.
Income tax expense
30,13 mjd.
-86,62 mjd.
49,46 mjd.
-36,49 mjd.
Effective tax rate
22,51%
19,04%
30,40%
-23,40%
Other operating expenses
67,13 mjd.
-64,27 mjd.
53,17 mjd.
-21,52 mjd.
Net income
103,64 mjd.
-368,47 mjd.
113,20 mjd.
192,43 mjd.
Net profit margin
8,70%
-33,66%
9,28%
16,21%
Earnings per share
-
-
-
-
Interest and investment income
181,35 mjd.
-
-
39,18 mjd.
Interest expense
-
-239,63 mjd.
-35,70 mjd.
-37,30 mjd.
Net interest expenses
181,35 mjd.
-239,63 mjd.
-35,70 mjd.
1,88 mjd.
Depreciation and amortization charges
-
-
-
-
EBITDA
319,89 mjd.
192,73 mjd.
363,66 mjd.
455,88 mjd.
Gain or loss from assets sale
358,00 m.
1,46 mjd.
-6,00 mjd.
8,84 mjd.
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
Google-programme